StoneX Group’s Immunogen Inc IMGN Stock Holding History

StoneX Group’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-16,227	Closed	-$115K	–	370
2017 Q2	$115K	Buy	+16,227	New	+$74.3K	0.04%	371

Other funds holding IMGN

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

StoneX Group's IMGN Position: Q3 2017 in Review

StoneX Group sold out of Immunogen Inc (IMGN) in Q3 2017, closing a stake of 16,227 shares — an estimated $115K sold.

StoneX Group first reported a position in IMGN in Q2 2017 and held it in 1 quarter. The position peaked at $115K in Q2 2017. 180 funds tracked by Wall St. Rank hold IMGN as of Q3 2017.

StoneX Group reported no remaining Immunogen Inc position as of Q3 2017 after selling out during the quarter.
StoneX Group sold 16,227 Immunogen Inc shares in Q3 2017, an estimated $115K.
StoneX Group first reported a position in Immunogen Inc in Q2 2017 and held it in 1 quarter.
StoneX Group's Immunogen Inc position peaked at $115K in Q2 2017.
180 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2017.

Based on StoneX Group's 13F filing for Q3 2017, filed 13 Nov 2017.